GleamWall
中文EN

INBX Inhibrx Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%

Returns

ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.00M$0—$0$0$1.30M$0$100,000
R&D expense$25.97M$23.90M$25.22M$25.35M$28.54M$22.27M$36.88M$33.37M
SG&A expense$7.77M$8.25M$5.71M$5.57M$5.28M$6.42M$6.02M$16.66M
Operating income-$31.73M-$32.15M-$30.93M-$30.92M-$33.81M-$27.39M-$42.90M-$49.93M
Interest expense$8.75M$5.69M$3.51M$3.19M$3.18M$3.14M$2.69M$0
Pretax income-$38.73M-$36.65M-$33.44M-$32.83M-$35.26M-$28.65M-$43.31M-$47.87M
Income tax$0$3,000$0$0$0$2,000$0$0
Net income-$38.73M-$36.65M-$33.44M-$32.83M-$35.26M-$28.65M-$43.31M-$47.87M
EBITDA-$31.22M-$31.63M-$30.39M-$30.36M-$33.23M-$26.73M-$42.23M-$49.24M
EPS (basic)-2.46-2.34-2.15—-2.28-1.85-2.80—
EPS (diluted)-2.46-2.34-2.15—-2.28-1.85-2.80—
Weighted avg. shares (diluted)15.72M15.67M15.59M—15.48M15.47M15.47M—
Balance sheet
Cash & equivalents$199.47M$133.34M$161.66M$124.22M$153.09M$186.57M$216.52M$152.60M
Current assets$206.87M$142.21M$171.34M$132.83M$161.42M$193.96M$223.39M$160.40M
PP&E, net$2.17M$2.69M$3.20M$3.73M$4.31M$4.88M$5.55M$6.20M
Total assets$220.29M$154.22M$183.97M$146.48M$177.47M$212.12M$242.64M$180.77M
Current liabilities$27.30M$28.06M$26.51M$33.80M$35.98M$38.94M$43.64M$40.73M
Long-term debt$276.70M$176.28M$174.99M$100.56M$99.92M$99.28M$98.65M$0
Total debt$276.70M$176.28M$174.99M$100.56M$99.92M$99.28M$98.65M$0
Total liabilities$306.17M$207.20M$205.00M$138.49M$140.64M$143.56M$148.20M$47.18M
Shareholders' equity-$85.88M-$52.98M-$21.04M$7.99M$36.83M$68.56M$94.44M$133.58M
Net debt$77.23M$42.94M$13.34M-$23.66M-$53.17M-$87.29M-$117.87M-$152.60M
Shares outstanding14.76M14.71M14.61M14.58M14.50M14.48M14.48M14.48M
Cash flow statement
Operating cash flow-$34.60M-$29.92M-$38.03M-$30.12M-$33.82M-$29.95M-$35.90M-$43.72M
Capital expenditure$29,000$0$0$0$10,000$0$21,000$16,000
Free cash flow-$34.63M-$29.92M-$38.03M-$30.12M-$33.83M-$29.95M-$35.92M-$43.74M
Investing cash flow-$29,000$0$0$0-$7,000$0-$21,000-$16,000
Financing cash flow$100.76M$1.60M$75.46M$1.25M$352,000$0$99.84M$0
Depreciation & amortization$514,000$523,000$537,000$564,000$582,000$662,000$675,000$689,000
Stock-based compensation$3.34M$3.10M$2.65M$2.74M$3.17M$2.77M$2.45M$2.98M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.